Viking Therapeutics reported Q2 2026 results highlighting full enrollment in Phase 3 trials of VK2735, a dual GLP-1/GIP agonist for obesity, with positive prior Phase 2 data showing significant weight loss and good tolerability. The company plans to start Phase 3 trials for an oral VK2735 formulation in Q4 2026, potentially the first oral dual agonist on the market, offering flexible treatment options. Viking also initiated a Phase 1 trial for VK3019, an amylin receptor agonist, expanding its obesity treatment pipeline. Financially, Viking ended Q2 with $502 million in cash but reported increased net losses due to higher R&D and administrative expenses. Upcoming data on maintenance dosing for VK2735 is expected in Q3 2026, supporting long-term weight management strategies.
Guangzhou's Nansha District is rapidly advancing as a global cross-border trade hub with its state-of-the-art automated container terminal and integrated multimodal transport system. In 2025, Nansha Port handled over 22.6 million TEUs and operates 18...
Nord Precious Metals Mining Inc., focused on high-grade silver mining in Northern Ontario, announced that CEO Frank J. Basa will present live at the OTCQB Virtual Investor Conference on August 5, 2026. The event allows investors to engage directly wi...
YieldMax ETFs declared weekly distributions for their Group 1 ETFs, effective August 6, 2026. Distribution rates vary widely across ETFs, reflecting different investment strategies and associated risks, including semiconductor, AI, crypto, metals, an...
The global military drone market is expected to grow from $16.5 billion in 2025 to $42.8 billion by 2035, at a CAGR of 10%. Growth is fueled by AI-powered autonomous systems, defense modernization, and rising demand for surveillance, electronic warfa...
Man Group PLC has disclosed a 1.66% interest in Senior Plc's ordinary shares, totaling 6,962,764 shares, held through cash-settled derivatives as of August 3, 2026. The stake was increased by 104,804 shares via an equity swap transaction priced at ap...
